DexCom, Inc.

As of June 30, 2026, DexCom, Inc. carries a market capitalization of 468.86B, placing it among publicly traded companies globally. Its enterprise value stands at 459.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DexCom, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, DexCom, Inc. has 377.40M shares outstanding.

As of June 30, 2026, DexCom, Inc. trades at a trailing price-to-earnings ratio of 27.47. The price-to-sales ratio is 5.53, and the price-to-book ratio stands at 10.24.

As of June 30, 2026, DexCom, Inc. trades at an EV/EBITDA multiple of 18.73 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.08 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. DexCom, Inc. trades at an EV/FCF ratio of 18.55, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 459.27B versus a market cap of 468.86B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, DexCom, Inc. maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 53.35, indicating elevated leverage, while an interest coverage ratio of 93.55 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, DexCom, Inc. posted a return on equity (ROE) of 38.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 19.21 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.51, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 22.05, useful for judging operating efficiency across full business cycles. The company generates approximately 7.97M in revenue per employee across its workforce of 10,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.88 indicates how many times DexCom, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, DexCom, Inc. recorded 4.90B in income tax expense. That works out to an effective tax rate of 21.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.36B, leaving 17.47B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, DexCom, Inc.'s stock has gained approximately 29.26% over the past 52 weeks. The 50-day moving average sits at 1,347.15, while the 200-day moving average is 1,411.58.

Over the twelve months ended June 30, 2026, DexCom, Inc. generated 86.82B in revenue and converted that into 17.47B in net income, yielding earnings per share of 43.94. EBITDA reached 24.52B, while operating income came in at 19.90B.

As of June 30, 2026, DexCom, Inc. holds 34.02B in cash and equivalents against 24.43B in total debt, resulting in a net debt position of 2.41B. Total book value stands at 45.80B, with working capital of 30.21B providing operational flexibility.

DexCom, Inc. produced 30.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.00B in capital expenditures, free cash flow totaled 24.55B - equivalent to 63.55 per share.

Over the twelve months ended June 30, 2026, DexCom, Inc. posted a gross margin of 62.47, reflecting its pricing power and cost economics. The operating margin of 22.92 and net profit margin of 20.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.97, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to DexCom, Inc. shareholders.

DexCom, Inc.'s most recent stock split took place on July 6, 2022 with a 1:4 split ratio.

As of June 30, 2026, DexCom, Inc. has an Altman Z-Score of 6.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.